BACKGROUND: Rift Valley fever (RVF) is an emerging arthropod-borne zoonoses of global agricultural and public health importance. In December 2006, an RVF outbreak was recognized in Kenya which led to the deployment of international response laboratory teams to the area. OBJECTIVES: A field laboratory was operated in Malindi, Kenya to provide safe sample handling and molecular testing for RVF virus (RVFV) as well as selected other pathogens for differential diagnosis. STUDY DESIGN: Safe sample handling was carried out using a negative pressure flexible film isolator (glovebox) and commercial reagents to inactivate clinical specimens and purify nucleic acid. Whole blood was routinely used for diagnostic testing although paired plasma samples were also tested in select cases. Subsequently, human macrophages were tested in vitro for their susceptibility to RVFV. RESULTS: The field laboratory received samples from 33 individuals and a definite laboratory diagnosis was provided in 16 of these cases. Using molecular diagnostic techniques, RVFV was more consistently detected in whole blood than in plasma samples most likely due to association of RVFV with blood cells. Subsequent in vitro studies identified macrophages as a target cell for RVFV replication. CONCLUSIONS: RVFV appears to replicate in blood cells such as macrophages. Thus, the sensitivity of molecular diagnostic testing is improved if whole blood is used as the clinical specimen rather than plasma or serum. Published by Elsevier B.V.
BACKGROUND:Rift Valley fever (RVF) is an emerging arthropod-borne zoonoses of global agricultural and public health importance. In December 2006, an RVF outbreak was recognized in Kenya which led to the deployment of international response laboratory teams to the area. OBJECTIVES: A field laboratory was operated in Malindi, Kenya to provide safe sample handling and molecular testing for RVF virus (RVFV) as well as selected other pathogens for differential diagnosis. STUDY DESIGN: Safe sample handling was carried out using a negative pressure flexible film isolator (glovebox) and commercial reagents to inactivate clinical specimens and purify nucleic acid. Whole blood was routinely used for diagnostic testing although paired plasma samples were also tested in select cases. Subsequently, human macrophages were tested in vitro for their susceptibility to RVFV. RESULTS: The field laboratory received samples from 33 individuals and a definite laboratory diagnosis was provided in 16 of these cases. Using molecular diagnostic techniques, RVFV was more consistently detected in whole blood than in plasma samples most likely due to association of RVFV with blood cells. Subsequent in vitro studies identified macrophages as a target cell for RVFV replication. CONCLUSIONS:RVFV appears to replicate in blood cells such as macrophages. Thus, the sensitivity of molecular diagnostic testing is improved if whole blood is used as the clinical specimen rather than plasma or serum. Published by Elsevier B.V.
Authors: William S Probert; Kimmi N Schrader; Nhi Y Khuong; Susan L Bystrom; Margot H Graves Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: Christian Drosten; Stephan Göttig; Stefan Schilling; Marcel Asper; Marcus Panning; Herbert Schmitz; Stephan Günther Journal: J Clin Microbiol Date: 2002-07 Impact factor: 5.948
Authors: Trevor Shoemaker; Carla Boulianne; Martin J Vincent; Linda Pezzanite; Mohammed M Al-Qahtani; Yagub Al-Mazrou; Ali S Khan; Pierre E Rollin; Robert Swanepoel; Thomas G Ksiazek; Stuart T Nichol Journal: Emerg Infect Dis Date: 2002-12 Impact factor: 6.883
Authors: Lee D Smythe; Ina L Smith; Greg A Smith; Michael F Dohnt; Meegan L Symonds; Leonie J Barnett; David B McKay Journal: BMC Infect Dis Date: 2002-07-08 Impact factor: 3.090
Authors: Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt Journal: Vector Borne Zoonotic Dis Date: 2013-08-20 Impact factor: 2.133
Authors: Marc-Antoine de La Vega; Grazia Caleo; Jonathan Audet; Xiangguo Qiu; Robert A Kozak; James I Brooks; Steven Kern; Anja Wolz; Armand Sprecher; Jane Greig; Kamalini Lokuge; David K Kargbo; Brima Kargbo; Antonino Di Caro; Allen Grolla; Darwyn Kobasa; James E Strong; Giuseppe Ippolito; Michel Van Herp; Gary P Kobinger Journal: J Clin Invest Date: 2015-11-09 Impact factor: 14.808
Authors: Gabriel Fitzpatrick; Florian Vogt; Osman B Moi Gbabai; Tom Decroo; Marian Keane; Hilde De Clerck; Allen Grolla; Raphael Brechard; Kathryn Stinson; Michel Van Herp Journal: J Infect Dis Date: 2015-05-22 Impact factor: 5.226